Molecular Imaging

Catch up on the first three episodes of our Molecular Imaging in Focus series featuring interviews with Gary Ulaner, MD, PhD, Louise Emmett, MBChB, FRACP, FAANMS, MD, and Jeremie Calais, MD, PhD.

Catch up on the most-well viewed radiology content in March 2026.

In a recent interview, Louise Emmett, MBChB, FRACP, FAANMS, MD, discussed recent findings from the Co-PSMA trial demonstrating enhanced detection of biochemical recurrence of prostate cancer with the PET agent 64Cu-SAR-bisPSMA.

Can the radioligand therapy 177Lu-PSMA-617 have an impact in older taxane-naïve men with mCRPC? Could we see the development of more combination therapies for patients with prostate cancer? Will emerging theranostics be effective in other targets beyond PSMA? Daniel George, M.D., addressed these topics and more in a recent interview.

Catch up on the top radiology content of the past week.

Emerging PSMA PET-based nomograms offered 12 percent and 14 percent higher AUCs than the European Association of Urology risk score for risk stratification of patients with biochemical recurrence of prostate cancer, according to an international, registry-based study involving over 11,000 patients.

Catch up on the top radiology content of the past week.

Catch up on a variety of new FDA clearances and approvals in radiology from the past week.

Catch up on the top radiology content of the past week.

Designed to enhance product stability at higher radioactive concentrations, the PSMA PET imaging agent Pylarify TruVu (piflufolastat F 18) may facilitate enhanced supply flexibility and access for men with suspected recurrence or metastasis of prostate cancer.

In a recent interview, Ashesh Jani, M.D., discussed pertinent findings in two post-hoc studies from the SPOTLIGHT trial that examined the efficacy of 18F-flotufolastat PET/CT for detecting biochemical recurrence and bone metastases in patients with prostate cancer.

Full approval of PNT2003, a radioequivalent of Lutathera (lutetium Lu 177 dotatate), is subject to a 30-month stay — triggered by a Hatch-Waxman patent litigation — that is reportedly set to expire in June 2026.

Catch up on the top radiology content of the past week.

In a recent interview, Brian Helfand, M.D., Ph.D., discussed key findings from a multicenter prospective trial, presented at the ASCO-GU symposium, that compared the PET radiotracers 18F-flotufolastat and 18F piflufolastat for urinary radioactivity and detection of PCa recurrence.

Catch up on the most-well viewed radiology content in February 2026.

In a recent interview from the ASCO-GU conference. Daniel George, M.D., discussed new study findings with 177Lu-PSMA-617 for the treatment of older taxane-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) and potential implications for future research.

Catch up on the most well-viewed video interviews from Diagnostic Imaging in February 2026.

The AKY-1189 agent was designed for targeting of positive Nectin-4 expressing tumors that reportedly occur in 80 to 90 percent of patients with urothelial cancer.

Catch up on the top radiology content of the past week.

In comparison to 68Ga-PSMA-11, 64Cu-SAR-bisPSMA more than doubled the rate of detection for prostate cancer recurrence and facilitated changes to the treatment plan in 44 percent of patients, according to research to be presented at the upcoming European Association of Urology (EAU) Congress.

Catch up on the top radiology content of the past week.

The use of the SPECT/CT agent 99mTc-maraciclatide may enhance detection and differentiation for interstitial lung disease, which is associated with a large variety of disorders.

In a recent interview, Gary Ulaner, M.D., Ph.D., discussed preliminary research with the newly patented 61Cu-NU101 radiodiagnostic agent and the potential with the agent’s half-life in expanding access to molecular imaging for prostate cancer detection.

Researchers found that PSMA PET/CT offered 18 percent higher accuracy than mpMRI in detecting bilateral intraprostatic disease, according to a new study involving patients with intermediate or high-risk prostate cancer.

Catch up on the top radiology content of the past week.